Quantcast

Latest Anti-diabetic drug Stories

2008-08-05 18:00:09

By Kevin Leibrock, Hendricks County Flyer, Avon, Ind. Aug. 5--DANVILLE -- Nearly one out of every 12 Americans has diabetes, according to a report by the Centers for Disease Control and Prevention. For many people -- including 27-year-old John Colvin -- living with the treatable disease has become routine. The Hume, Ill., native was diagnosed with Type I diabetes at eight weeks of age, but began seeing Danville-based specialist Dr. Samuel Wentworth as an 8-year-old to check his...

2008-07-31 09:00:28

AtheroGenics, Inc. (NASDAQ: AGIX), a pharmaceutical company focused on the treatment of chronic inflammatory diseases, today announced top-line results from its ANDES Phase 3 clinical trial of AGI-1067 (succinobucol) for the treatment of Type 2 diabetes demonstrating that both doses (75mg and 150mg) of AGI-1067 met the primary efficacy endpoint of the reduction in glycosylated hemoglobin (A1c) versus placebo at the end of the study's six month dosing regimen. "We are pleased that the ANDES...

2008-07-29 18:00:20

Metabasis Therapeutics (Nasdaq: MBRX) announced today that an oral presentation summarizing the results from the Company's Phase 2a clinical trial for MB07803 will be given at the World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy), to be held in Barcelona, Spain, October 30 to November 2, 2008. MB07803 is the Company's second-generation fructose-1,6-bisphosphatase (FBPase) inhibitor for the treatment of type 2 diabetes. As reported in April,...

2008-07-18 06:00:20

Research and Markets (http://www.researchandmarkets.com/research/246fc3/innovations_in_the) has announced the addition of the "Innovations in the Management of Diabetes: Next Generation Treatments and Market Dynamics" report to their offering. Business Insights' portfolio of healthcare management reports is designed to help you make well informed and timely business decisions. We understand the problems facing today's pharmaceutical and healthcare executives when trying to drive your...

2008-07-14 09:01:11

DiaMedica Inc. (TSX VENTURE: DMA) ("DiaMedica"), a drug discovery and development company focused on novel treatments for Type 2 diabetes, today announces top-line results of a Phase II trial showing that its investigational drug DM-83 met the primary endpoint by lowering peak insulin levels in diabetic patients. The single dose, placebo controlled, single-blind, cross-over study in patients with Type 2 diabetes, using a meal tolerance model showed a statistically significant reduction (23%)...

2008-07-08 12:01:16

SAN MATEO, Calif., July 8 /PRNewswire/ -- After meeting on July 1st and 2nd an FDA advisory panel recommended that all new diabetes drugs should undergo trials to rule out cardiovascular risk. 85% of US cardiologists and 65% of US endocrinologists agree with this recommendation, according to AlphaDetail Inc., a leader in cardiovascular and metabolic primary market research and key opinion leader mapping solutions to the Global Life Sciences Industry. On July 3rd AlphaDetail launched its...

2008-07-07 00:00:06

AN estimated one in 10 middle-aged Malaysians has diabetes. But that's not what worries experts the most. Another one in five has what doctors call "pre-diabetes". The number of pre-diabetics is expected to climb as the nation gets older, fatter and more sedentary. Pre-diabetics are not only at risk of developing diabetes but are also at risk of suffering heart attacks, strokes, kidney failure, blindness and nerve damage. "Your risk of heart attack or stroke is two to four times...

2008-06-29 03:00:04

The U.S. Food and Drug Administration is considering new standards for drugs designed to treat diabetes, The Wall Street Journal reports. The agency is considering benchmarks that would require pharmaceutical companies to prove the drugs reduce the risk of heart attack or increase the life span of diabetics, the newspaper said. Current benchmarks like reduction in blood sugar are easier to measure. Two large scientific studies found no evidence that aggressive reduction in blood sugar...

2008-06-24 09:03:24

Akesis Pharmaceuticals, Inc. (OTCBB:AKES), an emerging diabetes drug-development company, today announced it plans to begin a 13-week preclinical safety program for AKP-020, a novel vanadium compound that has shown considerable potential as a treatment for Type 2 diabetes. The studies will be conducted by Charles River Laboratories, and follows a recently completed 28-day preclinical safety program, also performed by Charles River. Earlier this month the company also announced positive...

2008-06-19 15:00:08

To: NATIONAL EDITORS Contact: AHRQ Public Affairs, +1-301-427-1998, or +1-301-427- 1539 ROCKVILLE, Md., June 19 /PRNewswire-USNewswire/ -- Pastillas para la diabetes tipo 2,a new consumer guide for Hispanic adults who have type 2 diabetes and need information to help them compare various oral medications for their illness, has been released by the Agency for Healthcare Research and Quality. Diabetes is one of the most serious health issues facing Hispanics in the United States. AHRQ...


Word of the Day
toccata
  • In music, a work for a keyboard-instrument, like the pianoforte or organ, originally intended to utilize and display varieties of touch: but the term has been extended so as to include many irregular works, similar to the prelude, the fantasia, and the improvisation.
This word is Italian in origin, coming from the feminine past participle of 'toccare,' to touch.
Related